New trial results suggest retatrutide may produce greater average weight loss than tirzepatide, but the comparison is more complicated than the headlines imply. Here is what the evidence actually shows, why cross-trial numbers have real limits, and what it means for UK patients currently on Mounjaro.
Results emerging from retatrutide’s clinical development programme have generated significant excitement, with some reports suggesting the drug could outperform tirzepatide — sold in the UK as Mounjaro — for weight loss.
The figures being quoted are striking. But there is an important catch: this is not yet a true head-to-head comparison.
Retatrutide and Mounjaro have been studied in different clinical trials, involving different patients and different treatment periods. So while the latest results strengthen the case for retatrutide as a potentially powerful new weight-loss medicine, they do not prove that it is better than Mounjaro.
For UK patients, there is another important distinction. Mounjaro is an authorised medicine that can be prescribed in the UK. Retatrutide remains an investigational drug and is not currently authorised by the MHRA.
What the Retatrutide vs Mounjaro Trial Data Actually Shows
Retatrutide, developed by Eli Lilly, is a triple-hormone receptor agonist being investigated for obesity and related conditions.
Results from its clinical development programme have produced average weight-loss figures above 20% in some groups, putting retatrutide among the most effective obesity medicines studied so far.
Tirzepatide already has similarly impressive evidence behind it. In the landmark SURMOUNT-1 trial, participants receiving the highest 15mg dose of tirzepatide lost an average of approximately 20.9% of their starting body weight after 72 weeks.
These results make comparisons between retatrutide and Mounjaro inevitable.
But comparing percentages from different trials is not the same thing as putting the two medicines against each other in a single study.
Another experimental medicine attracting attention is amycretin, being developed by Novo Nordisk.
Amycretin combines GLP-1 and amylin receptor activity rather than using the same three-receptor approach as retatrutide. In a small Phase 1b/2a study involving people with overweight or obesity, the highest-dose group achieved estimated average weight loss of approximately 24.3% after 36 weeks.
That is an eye-catching result, but it came from a small early-stage study and should not be treated as directly equivalent to evidence from much larger Phase 3 obesity trials.
Semaglutide, the active ingredient in Wegovy, provides another useful benchmark. In the STEP 1 Phase 3 trial, participants receiving semaglutide 2.4mg lost an average of around 14.9% of their starting body weight after 68 weeks.
Taken together, the results show how quickly obesity treatment is developing.
They do not, however, give us a definitive league table showing which medicine is best.
Why This Is Not a True Head-to-Head Comparison
This is the most important point behind the headlines.
The weight-loss figures for retatrutide, tirzepatide, semaglutide and amycretin come from separate clinical trials.
Those trials can differ in their patient populations, eligibility criteria, doses, treatment duration, trial design and statistical methods.
That matters enormously.
If one group loses 22% in one trial and another loses 20% in a completely different trial, it is tempting to conclude that the first medicine is 2 percentage points better.
Clinical evidence does not work quite that simply.
Differences in the people enrolled, how treatment was delivered, how long patients remained on treatment and how the results were analysed can all affect the final numbers.
Cross-trial comparisons can help researchers and clinicians understand where a new medicine might sit within the wider treatment landscape, but they cannot reliably establish that one medicine is superior to another.
A properly designed randomised trial comparing retatrutide and tirzepatide under the same conditions would provide much stronger evidence.
For now, the cautious conclusion is that retatrutide appears capable of producing weight loss in a similar — and potentially somewhat higher — range than tirzepatide.
Whether it genuinely outperforms Mounjaro remains to be established.
Why Retatrutide Works Differently From Mounjaro
There is a genuine biological reason why researchers are so interested in retatrutide.
Mounjaro contains tirzepatide, which activates two hormone receptors:
GLP-1 and GIP.
Retatrutide activates those same two pathways but adds a third:
the glucagon receptor.
That is why retatrutide is often described as a “triple agonist”.
GLP-1 helps regulate appetite, slows gastric emptying and influences blood glucose. GIP also plays a role in insulin response and energy metabolism.
Glucagon adds another dimension.
Among its effects, glucagon can influence energy expenditure and fat metabolism. Researchers hope that carefully combining glucagon receptor activation with GLP-1 and GIP activity can increase weight loss beyond what is possible through the other pathways alone.
It is not simply a case of adding another appetite suppressant.
The three signals interact with different aspects of metabolism.
There is also a reason this balance needs careful clinical testing. Glucagon can raise blood glucose as well as affecting energy expenditure and fat metabolism, so combining these pathways safely within a single medicine is complex.
Understanding the long-term safety, tolerability and metabolic effects of retatrutide is therefore just as important as establishing how much weight patients lose.
What This Means For UK Patients
For someone currently taking Mounjaro successfully in the UK, the latest retatrutide results are interesting — but they do not currently change the available treatment options.
Retatrutide has not received UK marketing authorisation from the MHRA.
It therefore cannot currently be prescribed as an authorised retatrutide medicine through a UK pharmacy or weight-loss clinic.
There has been some UK regulatory activity around the drug. In July 2026, the MHRA agreed a paediatric investigation plan relating to retatrutide for obesity and overweight.
That is part of the medicine-development and regulatory process. It is not an approval to sell or prescribe retatrutide in the UK, and it should not be interpreted as evidence that a UK launch is imminent.
If Eli Lilly completes the necessary clinical programme and seeks UK authorisation, retatrutide would still need to go through the appropriate regulatory process before an authorised product could become available.
There is therefore no clinically established reason for somebody doing well on Mounjaro to stop treatment simply because retatrutide has produced promising trial results.
If you are considering changing or stopping an existing treatment, that is something to discuss with your prescriber.
The Grey-Market Retatrutide Problem
The excitement surrounding retatrutide has created another problem.
Products labelled “retatrutide” are already being advertised online by peptide sellers and research-chemical suppliers, despite there being no authorised retatrutide medicine available to UK patients.
This creates a crucial distinction.
The retatrutide being studied in pharmaceutical clinical trials is manufactured, stored, measured and administered under tightly controlled conditions.
A vial bought from an unregulated online supplier is not automatically the same thing simply because the label says “retatrutide”.
Without an authorised medicine and regulated supply chain, patients cannot reliably know whether such a product contains the stated ingredient, whether the dose is accurate, whether it has been manufactured or stored appropriately, or whether it contains contaminants.
Promising clinical trial results therefore do not make grey-market retatrutide safe.
The better retatrutide performs in clinical trials, the more tempting these products may become — which makes that distinction increasingly important.
You can read more about the drug’s development, UK status and availability in our Retatrutide UK Guide.
For a broader comparison of the medicines currently available and those still in development, see our Weight Loss Jabs and Pills Compared guide.
And if you are currently considering an authorised tirzepatide treatment, our Mounjaro UK Guide covers eligibility, dosing and how to access it safely.
Frequently Asked Questions
Is Retatrutide Better Than Mounjaro?
We don’t know yet.
Retatrutide has produced extremely strong weight-loss results in clinical trials, and some results suggest it may be capable of greater average weight loss than tirzepatide.
However, comparing results from separate trials cannot establish that retatrutide is definitively better than Mounjaro.
A direct randomised comparison under the same conditions would provide much stronger evidence.
Has Retatrutide Been Directly Compared With Mounjaro?
The figures currently generating headlines largely come from separate clinical trials rather than a published randomised trial directly comparing retatrutide with tirzepatide under identical conditions.
That means claims that retatrutide has already “beaten” Mounjaro should be treated cautiously.
Can I Get Retatrutide in the UK Now?
There is currently no MHRA-authorised retatrutide medicine available to UK patients.
Products advertised online as retatrutide by peptide or research-chemical suppliers are not the same as accessing an authorised prescription medicine through a regulated UK supply chain.
Should I Stop Mounjaro and Wait for Retatrutide?
There is currently no authorised retatrutide medicine in the UK to switch to and no guaranteed UK launch date.
If Mounjaro is working for you, promising results from an experimental medicine are not by themselves a reason to stop an established treatment.
Any decision to stop or change a prescribed medicine should be discussed with your prescriber.
Why Might Retatrutide Produce More Weight Loss Than Mounjaro?
Mounjaro activates GLP-1 and GIP receptors, while retatrutide activates GLP-1, GIP and the glucagon receptor.
Researchers believe the additional glucagon activity may increase energy expenditure and influence fat metabolism, potentially contributing to greater weight loss.
Whether that translates into a clinically meaningful advantage over Mounjaro for most patients still needs to be established.
What About Amycretin?
Amycretin is another experimental obesity medicine, developed by Novo Nordisk.
Instead of targeting GLP-1, GIP and glucagon like retatrutide, it combines GLP-1 and amylin receptor activity.
A small Phase 1b/2a obesity study produced estimated average weight loss of around 24% at the highest dose after 36 weeks, making amycretin another potentially important next-generation treatment.
However, it remains investigational and has not received MHRA authorisation.
This article is for information purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting, stopping or changing any treatment.
